Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 11/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 10/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 10/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24176467 | 1.00 | GNAO1 (0.38) | GNAO1GNAI3GNAI1NPC1TP53 | |
| SCHEMBL20243863 | 0.92 | GNAI3 (0.32) | GNAO1GNAI3GNAI1NPC1 | |
| SCHEMBL18799744 | 0.84 | GNAO1 (0.38) | GNAO1GNAI3GNAI1NPC1TP53 | |
| SCHEMBL21677540 | 0.84 | GNAO1 (0.38) | GNAO1GNAI3GNAI1NPC1TP53 | |
| SCHEMBL22068564 | 0.84 | GNAO1 (0.38) | GNAO1GNAI3GNAI1NPC1TP53 | |
| SCHEMBL27279285 | 0.84 | GNAO1 (0.38) | GNAO1GNAI3GNAI1NPC1TP53 | |
| SCHEMBL21214015 | 0.84 | GNAO1 (0.38) | GNAO1GNAI3GNAI1NPC1TP53 | |
| SCHEMBL22921027 | 0.83 | L3MBTL1 (0.35) | GNAO1GNAI3GNAI1TSHRTHRB | |
| SCHEMBL5295320 | 0.83 | L3MBTL1 (0.35) | GNAO1GNAI3GNAI1TSHRTHRB | |
| SCHEMBL18671809 | 0.83 | L3MBTL1 (0.35) | GNAO1GNAI3GNAI1TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779912-B2 | Synthesis and characterization of Ru alkylidene complexes | UMICORE AG & CO. KG (DE) | 2023-10-10 | — | — | US | disclosed |
| US-20230293429-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20210394167-A1 | SYNTHESIS AND CHARACTERIZATION OF RU ALKYLIDENE COMPLEXES | UMICORE AG & CO. KG (DE) | 2021-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210394167-A1 | SYNTHESIS AND CHARACTERIZATION OF RU ALKYLIDENE COMPLEXES | PORCN, ORC3, COASY | GNAO1 3607/4885GNAI3 3520/4885GNAI1 3716/4885 |
| US-11779912-B2 | Synthesis and characterization of Ru alkylidene complexes | PORCN, ORC3, COASY | GNAO1 3607/4885GNAI3 3520/4885GNAI1 3716/4885 |
| US-20230293429-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | GNAO1 3025/4885GNAI3 1418/4885GNAI1 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.